KEYTRUDA® (pembrolizumab)(Merck)은 Solid Tumor, Adult 표적 항체로, Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT02444741). PK: t½ 3 h. 차별점: novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo.
Solid Tumor, Adult
Solid Tumors
Recruiting
bispecific antibodies: progress and prospects in cancer therapy
vedotin plus pembrolizumab in advanced urotheli
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
PD-L1 expression
escape driven by multiple mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
KEYTRUDA® (pembrolizumab)(Merck)은 Solid Tumor, Adult 표적 항체로, Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT02444741). PK: t½ 3 h. 차별점: novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo.
Solid Tumor, Adult
Solid Tumors
Recruiting
bispecific antibodies: progress and prospects in cancer therapy
vedotin plus pembrolizumab in advanced urotheli
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
PD-L1 expression
escape driven by multiple mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.